Intensity-modulated Radiotherapy in the Treatment of Lung Cancer

Clinical Oncology

Volumn 24, Issue 7, 2012, Pages 508-520

  Bezjak, A ^a   Rumble, R B ^b   Rodrigues, G ^c   Hope, A ^a   Warde, P ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d Provincial Head   (Canada)

Author keywords

Best practice; Clinical practice guideline; Evidence based medicine; IMRT; Intensity modulated radiotherapy; Lung cancer; Radiation treatment

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; DOSIMETRY; EMBASE; EVIDENCE BASED PRACTICE; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HEALTH PROGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; MEDLINE; OUTCOME ASSESSMENT; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW;

COHORT STUDIES; HUMANS; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 84864754807     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.05.007     Document Type: Article

References (39)

1. Canadian cancer statistics 2009 2009, National Cancer Institute of Canada, Canadian Cancer Society, Toronto.
2. Yang P., Allen M.S., Aubry M.C., et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005, 128(1):452-462.
3. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee. Radiother Oncol 1999, 52(2):137-148.
4. Liao Z.X., Komaki R.R., Thames H.D., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010, 76(3):775-781.
5. Yom S.S., Liao Z., Liu H.H., et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68(1):94-102.
6. Yuan S., Sun X., Li M., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007, 30(3):239-244.
7. Rosenzweig K.E., Fox J.L., Yorke E., et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005, 103(10):2118-2127.
8. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005, 61(2):318-328.
9. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63(2):324-333.
10. Wu K.L., Jiang G.L., Liao Y., et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 2003, 57(5):1336-1344.
11. Belderbos J.S., Heemsbergen W.D., De Jaeger K., Baas P., Lebesque J.V. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66(1):126-134.
12. Socinski M.A., Morris D.E., Halle J.S., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 2004, 22(21):4341-4350.
13. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24(30):4833-4839.
14. Onishi H., Araki T., Shirato H., et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 101(7):1623-1631.
15. Browman G., Levine M., Mohide E., et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13(2):502-512.
16. Bauman G., Rumble R.B., Chen J., et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 2012, 24.
17. Amanie J., Robinson D., Murray B., et al. Comparison of dose-escalated and intensity-modulated three-dimensional conformal radiotherapy plans in patients with localised non-small-cell lung cancer. Curr Oncol 2004, 11(3):93-97.
18. Chapet O., Khodri M., Jalade P., et al. Potential benefits of using non coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. Radiother Oncol 2006, 80(3):333-340.
19. Christian J.A., Bedford J.L., Webb S., Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 67(3):735-741.
20. Grills I.S., Yan D., Martinez A.A., et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003, 57(3):875-890.
21. Liu H.H., Wang X., Dong L., et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58(4):1268-1279.
22. Manon R.R., Jaradat H., Patel R., et al. Potential for radiation therapy technology innovations to permit dose escalation for non-small-cell lung cancer. Clin Lung Cancer 2005, 7(2):107-113.
23. Marnitz S., Stuschke M., Bohsung J., et al. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study. Strahlenther Onkol 2002, 178(11):651-658.
24. Mayo C.S., Urie M.M., Fitzgerald T.J., Ding L., Lo Y.C., Bogdanov M. Hybrid IMRT for treatment of cancers of the lung and esophagus. Int J Radiat Oncol Biol Phys 2008, 71(5):1408-1418.
25. Murshed H., Liu H.H., Liao Z., et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58(4):1258-1267.
26. Schwarz M., Alber M., Lebesque J.V., Mijnheer B.J., Damen E.M.F. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005, 62(2):561-570.
27. Sura S., Gupta V., Yorke E., Jackson A., Amols H., Rosenzweig K.E. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008, 87(1):17-23.
28. Underwood L.J., Murray B.R., Robinson D.M., et al. An evaluation of forward and inverse radiotherapy planning using Helax-TMS (version 6.0) for lung cancer patients treated with RTOG 93-11 dose-escalation protocol. Med Dosim 2003, 28(3):167-170.
29. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45(2):323-329.
30. Hope A.J., Lindsay P.E., El Naqa I., et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 2006, 65(1):112-124.
31. Rodrigues G., Lock M., D'Souza D., Yu E., Van Dyk J. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer - a systematic review. Radiother Oncol 2004, 71(2):127-138.
32. Rose J., Rodrigues G., Yaremko B., Lock M., D'Souza D. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol 2009, 91(3):282-287.
33. Kepka L., Bujko K., Zolciak-Siwinska A., Garmol D. Incidental irradiation of mediastinal and hilar lymph node stations during 3D-conformal radiotherapy for non-small cell lung cancer. Acta Oncol 2008, 47(5):954-961.
34. Rosenzweig K.E., Sura S., Jackson A., Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 2007, 25(35):5557-5561.
35. Kepka L., Maciejewski B., Withers R.H. Does incidental irradiation with doses below 50 Gy effectively reduce isolated nodal failures in non-small-cell lung cancer: dose-response relationship. Int J Radiat Oncol Biol Phys 2009, 73(5):1391-1396.
36. Steenbakkers R.J., Duppen J.C., Fitton I., et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006, 64(2):435-448.
37. Allen A.M., Czerminska M., Janne P.A., et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006, 65(3):640-645.
38. Kristensen C.A., Nottrup T.J., Berthelsen A.K., et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 2009, 92(1):96-99.
39. Rodrigues G.B., Roa W.H. In Regard to Allen et al.: Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma (Int J Radiat Oncol Biol Phys 2006;65:640-645). Int J Radiat Oncol Biol Phys 2007, 68(3):959.